The Potential of ENV-101 in Treating Idiopathic Pulmonary Fibrosis and Cancer | 2024 ATS
Editors spoke with Endeavor BioMedicines CEO John Hood about ENV-101, a novel Hedgehog inhibitor, in which he shared results on from a recent phase 2 clinical trial during this year's American Thoracic Society conference.
Rather than most current inhibitors that are used in cancer treatment, ENV-101 offers improved tolerability with fewer severe muscle spasms.
"The tolerability of the existing approved drugs for oncology is pretty poor," Hood shared. "They cause really bad muscle spasms and that doesn't happen with our drug. There are some muscle spasms, but they tend to be very mild and easily mitigated. So that's the biggest difference really, with our drug versus the approved."
The drug targets the Hedgehog signaling pathway in both idiopathic pulmonary fibrosis (IPF) and some cancers.
Following promising phase two results, Endeavor plans a phase two B trial this fall, aiming to begin phase three trials by 2026 for potential FDA approval.
Surya Bhatt Presents Results of NOTUS Trial for COPD Treatment | 2024 ATS
May 23rd 2024At the 2024 American Thoracic Society conference, Surya Bhatt, MD, director of the Lung Imaging Lab at the University of Alabama of Birmingham discussed the NOTUS trial, a second phase three trial for treating COPD with type two inflammation using dupilumab, following the BOREAS trial.
Read More
Ways Healthcare Differs Depending on the State an Immigrant Child Resides In | ATS 2024
May 22nd 2024Undocumented individuals are ineligible for the Affordable Care Act (ACA) or federally funded Medicaid, but some states offer state-sponsored coverage for certain immigration statuses, such as Temporary Protected Status.
Read More
Orangutan Health Offers Insights for Human Respiratory Disease | 2024 ATS
May 22nd 2024Speakers at the annual American Thoracic Society meeting discussed research looking at whether orangutan respiratory disease syndrome might have some of the same genetic causes as cystic fibrosis.
Read More
